Regulatory Considerations in Application of Encapsulated Cell Therapies
The encapsulation of tissue in semi-permeable membranes is a technology with high potential and in due time several new therapies based on this technology will be tested in clinical trials. Recent, new legislation requires that these investigational medicinal products used in clinical trials Phase I must be produced according to Good Manufacturing Practice (GMP). Consequently, the activities of GMP are expanding to the field of research and researchers might need to change developed protocols in order to meet GMP legislation. This chapters gives an overview of the overall guidelines covering GMP and more specific guidelines dealing with cell based therapies and gene therapy.
KeywordsMedicinal Product Good Manufacture Practice Investigational Medicinal Product Advance Medicinal Therapy Product Regulatory Consideration
Unable to display preview. Download preview PDF.
- 5.Immel BK. A brief history of the GMP’s: the power of storytelling. BioPharm International 2000; 61:26–36.Google Scholar
- 7.Möritz A. The new GMP environment for investigational medicinal products in the european union. BioProcess Int 2005; 3:28–38.Google Scholar
- 8.Rosin LJ. Regulatory affairs; If you didn’t write it down, it didn’t happen. 2006. BioProcess Int Supplement 2006; 4(3):16–23.Google Scholar
- 10.Mingam I, Dupraz-Poiseau A. Current and future frameworks for cell-and tissue-based products. Bio-Process International 2006; 4(5):12–17.Google Scholar